Abstract
The frequency and T-cell receptor beta-chain variable (TCRBV) patterns of peripheral CD4+CD25+ regulatory T-cells (Tregs) are ambiguously altered in chronic hepatitis B (CHB) patients following tenofovir disoproxil fumarate (TDF) treatment. Moreover, the clinical significance of these parameters in relation to hepatitis B e antigen (HBeAg) seroconversion (SC) is largely unknown. In this study, the circulation of Tregs in HBeAg-positive CHB patients was determined by flow cytometry, and the molecular profiles of frequent TCRBV patterns of Tregs were analyzed using a gene melting spectral pattern. The parameters, such as Treg frequency, the number of skewed TCRBV patterns, hepatitis B virus (HBV) DNA levels, and alanine aminotransferase (ALT) levels, were analyzed by comparing their associations in seroconverting and non-seroconverting patients following TDF treatment. The Treg frequency was significantly correlated with the ALT level in seroconverting but not in non-seroconverting patients. Similarly, skewed TCRBV patterns were remarkably associated with HBV DNA levels in the SC group. Six TCRBV families (BV3, BV11, BV12, BV14, BV20, and BV24) were more prevalent than other TCRBV members in seroconverting patients pretreated with TDF, while BV12, BV15, and BV22 were predominant in non-seroconverting patients during TDF treatment. Taken together, the preferential TCRBV patterns may be associated with immune responses related to SC. The dynamic frequency and skewed TCRBV patterns of peripheral Tregs could contribute to predicting SC in CHB patients. Moreover, the conserved TCRBV complementarity-determining region (CDR3) motif may be targeted to develop personalized immunotherapy for CHB patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McMahon BJ . The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45–55 .
Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G . Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009; 7: 15 .
Liaw YF . Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013; 33 Suppl 1:111–115 .
Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Akyuz F et al. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug resistant strains of hepatitis b virus. Liver Int 2015; 35: 2265–2274 .
Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763–773 .
Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM et al. Tenofovir versus entecavir in the treatment of chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2015; 59: 3168–3173 .
Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963–973.e9 .
Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol 2008; 129: 419–427 .
Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL . Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141–148 .
Yan Z, Zhou J, Zhang M, Fu X, Wu Y, Wang Y . Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127 low T cells in parallel with inhibiting hepatitis B virus DNA. Mol Med Rep 2014; 9: 2024–2030 .
TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol 2011; 31: 509–520 .
Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739–747 .
Attaf M, Huseby E, Sewell AK . Alphabeta T cell receptors as predictors of health and disease. Cell Mol Immunol 2015; 12: 391–399 .
Nikolich-Zugich J, Slifka MK, Messaoudi I . The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4: 123–132 .
Turner SJ, Doherty PC, McCluskey J, Rossjohn J . Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006; 6: 883–894 .
Yin Y, Li Y, Mariuzza RA . Structural basis for self-recognition by autoimmune T-cell receptors. Immunol Rev 2012; 250: 32–48 .
Yang J, Yi P, Wei L, Xu Z, Chen Y, Tang L et al. Phenotypes and clinical significance of circulating CD4(+)CD25(+) regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF). J Transl Med 2012; 10: 193 .
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132–143 .
Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G et al. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med 2014; 12: 183 .
Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2014; 63: 996–1004 .
Yang J, Chen J, He J, Xie Y, Zhu Y, Cao H et al. Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection. Cell Mol Immunol 2014; 11: 343–354 .
Yang J, Xu K, Zheng J, Wei L, Fan J, Li L . Limited T cell receptor beta variable repertoire responses to ESAT-6 and CFP-10 in subjects infected with Mycobacterium tuberculosis. Tuberculosis (Edinb) 2013; 93: 529–537 .
Yang J, Chen J, Mao H, Yi P, Yan D, He J et al. Skewed T-cell receptor beta chain variable gene (TCRBV) usage among different clinical types of patients with chronic HBV infection. FEMS Immunol Med Microbiol 2012; 65: 448–455 .
Schwanninger A, Weinberger B, Weiskopf D, Herndler-Brandstetter D, Reitinger S, Gassner C et al. Age-related appearance of a CMV-specific high-avidity CD8+ T cell clonotype which does not occur in young adults. Immun Ageing 2008; 5: 14 .
Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z . PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963–970 .
Buti M, Homs M . Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2012; 6: 413–421 .
Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother 2013; 57: 1790–1796 .
Martinet J, Leroy V, Dufeu-Duchesne T, Larrat S, Richard MJ, Zoulim F et al. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 2012; 56: 1706–1718 .
Belkaid Y, Rouse BT . Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6: 353–360 .
Ma H, Zhang HH, Wei L . Frequency of T-cell FoxP3(+) Treg and CD4(+)/CD8(+) PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J 2013; 126: 267–273 .
Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428–434 .
Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 59: 709–716 .
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–129 .
Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449–454 .
Sainz-Perez A, Lim A, Lemercier B, Leclerc C . The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 2012; 72: 3557–3569 .
Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014; 211: 2231–2248 .
Vonderheide RH, June CH . Engineering T cells for cancer: our synthetic future. Immunol Rev 2014; 257: 7–13 .
Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J et al. Monoclonal antibodies against GARP/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med 2015; 7: 284ra256 .
Tang H, Qiao J, Fu YX . Immunotherapy and tumor microenvironment. Cancer Lett 2016; 370: 85–90
Qasim W, Thrasher AJ . Progress and prospects for engineered T cell therapies. Br J Haematol 2014; 166: 818–829 .
Petersen J, Montserrat V, Mujico JR, Loh KL, Beringer DX, van Lummel M et al. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat Struct Mol Biol 2014; 21: 480–488 .
Miles JJ, Douek DC, Price DA . Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011; 89: 375–387 .
Baecher-Allan C, Wolf E, Hafler DA . Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells. Clin Immunol 2005; 115: 10–18 .
Li Z, Li D, Tsun A, Li B . FOXP3(+) regulatory T cells and their functional regulation. Cell Mol Immunol 2015; 12: 558–565 .
Acknowledgements
This study was supported by the Zhejiang province natural science foundation of China (LY15H030008), the National High-technology R&D Program of China (2013CB531406), the National Science and Technology Major Project (2012ZX10002-006), and the Fundamental Research Funds for the Central Universities (2013XZZX010, 2014XZZX008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Cellular & Molecular Immunology’s website.
Supplementary information
Rights and permissions
About this article
Cite this article
Yang, J., Sheng, G., Xiao, D. et al. The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4+CD25+ regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment. Cell Mol Immunol 13, 678–687 (2016). https://doi.org/10.1038/cmi.2015.100
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2015.100
Keywords
This article is cited by
-
Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects
BMC Infectious Diseases (2021)
-
Memory CD4+ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus
Genes & Immunity (2019)
-
CD4+CD25+ regulatory T-cells: a potential target for treating patients with chronic HBV infection
Cellular & Molecular Immunology (2017)
-
Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
Scientific Reports (2016)